CIO Monthly Letter. Teaming up to perform

Size: px
Start display at page:

Download "CIO Monthly Letter. Teaming up to perform"

Transcription

1 Chief Investment Office WM 26 June 2014 Teaming up to perform Mark Haefele Global Chief Investment Officer Wealth Management Tactically, we are overweight US and Eurozone equities, and US high yield and investment grade credit. However, we reduce the size of our overweight position in US high yield, and cut emerging market USD-denominated sovereign bonds to underweight, after strong performance in both segments year-to-date. As we approach the year s halftime whistle, the year has not been without its shocks. But what has actually surprised us most is the relative lack of surprises. We caution that the market calm does not lure investors into taking more risk than they can bear. Focus on a long-term strategic asset allocation with a tolerable level of risk is key. It is my honor to succeed my good friend Alex Friedman as Global CIO. Alex and I have invested together in one form or another for the past 20 years. My investment team and I have been involved in the CIO Monthly Letter since the beginning. So while you and I may not have been formally introduced, we already know each other. No level of involvement in formulating our UBS CIO House View can compare to having the privilege and responsibility of signing my name below. As we navigate the changing investment world together, I am certain of at least one thing: A healthy and open dialogue with you, our valued clients and partners, is a critical part of our transparent global investment process. More than 15 years ago, I wrote my first letter to partners who had entrusted me with their capital. I believed then and I believe now that the partner letter is one of the most important elements of a solid investment process. While not all our calls will be correct, we hope to maintain your trust and become better investors by clearly explaining our investment positions and inviting your feedback. Living in Europe during the football World Cup provides me plenty of free kicks to shoot for analogies, but more on these later. A surprising first half? CIO cannot pretend that it has got everything right this year. We did not forecast the so-called polar vortex, which sent US winter temperatures plummeting and brought economic output in much of the country to a near-standstill. Output contracted by 2.9% (annualized) in the first quarter. Growth will return in the second quarter, but some of this year s growth is simply lost. American consumers might buy a car in April if it was too cold in February, but they are unlikely to go to two restaurants in the springtime to make up for a foregone winter meal. We now forecast 2014 growth of 2.5%, from 3.0% at the start of the year. China s growth has also disappointed. The property market has proved weaker than we anticipated. Prices are declining month over month in 35 of China s 70 largest cities; this is ab This report has been prepared by UBS AG. Please see important disclaimers and disclosures at the end of the document. Past performance is no indication of future performance. The market prices provided are closing prices on the respective principal stock exchange. This applies to all performance charts and tables in this publication.

2 > > Growth in the US and China is likely to be lower than we intially expected. also the first month over month decline of the overall price index since May This is weighing on property investment and construction, and exports have failed to compensate. We now forecast 2014 GDP growth of 7.3%, down from 7.7% at the beginning of January. Eurozone growth, which we peg at 1.1% for the year, has broadly matched our expectations. But inflation has declined persistently, and the European Central Bank (ECB) was forced to cut its deposit rate into negative territory, a measure we were positioned for but hadn t expected the ECB to take. > > The rally in high grade bonds, and the intra-sector shift in equities surprised us. With respect to our investment recommendations, the rally in high grade bonds surprised us, and the intra-sector shift within equities in March and April was unhelpful for some of our thematic ideas. Equity long-short hedge fund managers, a segment we have been recommending within alternatives, were also not able to distinguish in the first half environment. Overall, however, as we approach the year s halftime whistle, what has actually surprised us most is the relative lack of surprises. > > What has actually surprised us most is the relative lack of surprises. Our global economic recovery thesis remains intact. Growth is on course to be 3.0%, with consensus forecasts in a very tight range. We have been right to overweight risky assets: global equities are up 6.4%, with 30-day realized market volatility now at its lowest level since 1996 (see Figure 1). Credit spreads have contracted, the euro has (finally!) begun to depreciate against the US dollar, and Brazil, our World Cup pick, topped its group. Keeping the game within reach Considering the recent past, when financial crises in the US and Eurozone threatened to upend the entire global economic order, one might be forgiven for savoring a world of few surprises. But in future an unsurprising world is likely to make many investors feel like returns are uninspiring, particularly in light of the strong performance of financial assets over recent years. From here we expect equity markets to deliver 7 8% p.a., high yield credit 4 5% p.a., and high grade bonds 0 3% p.a. (see Figure 2). > > A desire for higher returns should not lure investors into taking more risk than they can bear. In this environment, finding extra return is more crucial than ever. To help meet this need, CIO will strive to deliver clearly explained, strong-performing investment ideas. But a desire for higher returns than the market can offer should not lure investors into taking more risk than they can bear. Risks that appear bearable in an unsurprising world may become unbearable later. This is why, throughout the economic cycle, we still advise clients to hold well-diversified portfolios suitable for their risk tolerance. When we do see investors overreaching for returns, there are three common pitfalls we want to help you avoid: 1) leaving little margin for unexpected events; 2) not diversifying properly; and 3) taking on excess leverage. Investors must always allow for the unexpected. This year s World Cup is a front-of-mind example. Heading into the tournament, bookmakers priced an 85% chance that Spain, the reigning world and European champions and the No.1-ranked team globally, would qualify for the knockout round. We also expected them to qualify, but of course they didn t. Fig. 1: Realized 30-day volatility is at its lowest level since 1996 MSCI World 30-day volatility (%, annualized) 40 > > Equity markets are at their least volatile level since Source: Bloomberg, UBS, as of 25 June 2014 UBS CIO WM July

3 > > Investors must always allow for the unexpected. Bookmakers had priced an 85% chance that Spain would qualify from their group. At our recent Investor Forum (our monthly pre-match analysis meeting with top external fund managers) a participant likened this to current activity in financial markets. The options market is pricing in an 86% chance that Brent crude oil prices will not increase by more than 10% in the coming three months. This participant, like us, foresees prices remaining contained, but noted there is of course a possibility that the situation in Iraq could deteriorate and oil prices could rise. We therefore need to do our homework and assess the potential impact of the unexpected on our positions, a discipline all good investors should practice. With respect to this particular risk, we remain comfortable with our positioning, with oil trading at USD 114/bbl, but a 10 15% price increase would concern us due to the negative effect it would have on developed market economic growth. Second, in a world of low returns, it is understandable that investors are looking hard at every part of their portfolio to ensure that it will return as much as possible. For example, it may seem senseless in isolation to hold a fixed-rate bond fund in a rising yield environment, when a floating-rate fund is likely to deliver greater returns. Similarly, in isolation, holding high grade bonds at all may seem illogical when credit has a more favorable return outlook. > > Diversification is critical for improving the risk-return profile of portfolios overall. > > Building a portfolio is like picking a winning football team, including players in every position. > > Using leverage to boost returns involves increasing risk by an even greater factor. But a series of decisions that may make sense in isolation can lead to a far-from-ideal outcome. We prefer high yield credit to high grade bonds currently, but an investor who dedicates an entire portfolio to it is probably ill-advised. Similarly, we also believe that yields will rise, but swapping all fixed-rate bond exposure for floating rates is likely also not a good idea if the portfolio also contains growth-sensitive equities. Floating-rate credits and equities will likely be highly correlated, and portfolios therefore more volatile. Diversification is critical to mitigating idiosyncratic risks and improving the risk-return profile of portfolios overall. It s rather like picking a winning football team. At our April conference with leading fund managers in Davos, where World Cup fever had already started, one of our colleagues likened constructing a portfolio to selecting a football team. Every squad, no matter where it hails from, is made up of a goalkeeper, defenders, midfielders, and attackers. Every team develops a style suited to it while deploying players in those positions. Picking the best 11 players in the country isn t a winning strategy if those 11 do not include any defenders or a goalkeeper. For the record, I played as a center back in school, which was good preparation for portfolio management, but not the only role needed in a winning investment team. Finally, there is leverage. In a world of low returns and volatility, employing leverage can boost returns to levels we all may have grown accustomed to. Leveraging credit investments is particularly tempting thanks to the combination of relatively low borrowing costs and an ongoing hunt for yield. Investors must remember, however, that increasing returns using leverage involves increasing risk by an even greater factor, once we account for borrowing costs. For example, leveraging an investment by a factor of two in a credit instrument that yields 5% p.a. at a borrowing cost of 2% increases the return from 5% to 8% p.a., but doubles the amount of risk the investor assumes. > > We expect equity markets to deliver 7 8% p.a., high yield credit 4 5%p.a., and high grade bonds 0 3% p.a. over the next five years. Fig. 2: Expect lower returns from financial assets in the future 5-year historic returns, and 5-year UBS projections (%, annualized) Global Equities USD Cash EM Bonds US HY Bonds High grade Historical 5y Bonds Expected 5y Source: Bloomberg, UBS, as of 25 June 2014 US IG Bonds UBS CIO WM July

4 > > We advise focusing on developing and maintaining a long-term strategic asset allocation. > > Tactically, we are overweight US and Eurozone equities. Investors can avoid such pitfalls by maintaining a clear investing framework and making individual decisions in an overall portfolio context. We advise focusing first on developing and maintaining a long-term strategic asset allocation (SAA) that has a tolerable level of risk. We supplement the SAA with thematic and tactical asset allocation (TAA) ideas, which I detail below. If used in a risk-controlled way in the context of an overall portfolio, we believe they can boost returns relative to their risks. Our strategy for the second half of the match Entering the second half of 2014, we field a diversified set of tactical bets and are playing to win. We are overweight risk assets and, within our equity allocations, overweight US and Eurozone stocks. In the US, indicators suggest the economy is on track again after the 1Q slowdown. We think US economic growth should translate into mid-to-high single-digit earnings growth in percentage terms, in line with our expectation for equity performance. In the Eurozone, leading indicators are mixed, but have stayed in expansionary territory. The euro s strength has hurt earnings, but they will improve in year-over-year comparisons provided the euro does not reach new highs. Thus we see the potential for high singledigit percentage earnings growth thanks to a combination of economic expansion and margin improvement. > > In currencies, we play underweights in the euro and Swiss franc relative to the US dollar and British pound. > > We reduce the size of our US high yield credit overweight. Furthermore, the ECB continues to demonstrate its commitment to stimulating growth and inflation through its twin interest rate cuts and its apparent openness to pursuing an asset-backed security purchase program. This has bolstered our confidence in our underweight positions in the euro and the Swiss franc. We play these underweights relative to the US dollar and the British pound: after comments from Bank of England Governor Mark Carney, we now think a UK interest rate hike is likely near the end of the year. We remain underweight UK equities due to the negative effect the strong pound is having on the earnings of British companies. Elsewhere in currencies, we removed our underweight position in the Japanese yen relative to the US dollar early last week. Our move is not intended to signal that we expect Japanese yen strength. But since the Bank of Japan appears comfortable with current economic and inflation developments, and is potentially wary of more than 10% yearover-year energy inflation, the chance of the currency declining markedly in the months ahead has declined. In credit, we recommend a prudent overweight allocation to US high yield (HY), but moderately reduce the size of our overweight position this month. Spreads of 335bps still offer some scope for tightening (our six-month target is 300bps) and provide attractive carry, but potential gains from here are likely more limited. Fundamentals remain relatively strong: 27% of issuance is being used for mergers and acquisition and capital expenditure, compared with more than 50% back in 2007, and the use of creditor-unfriendly paid-in- > > Growth in the US is likely to match growth for EMBI-issuers for the first time in over ten years. Fig. 3: We project GDP growth for EMBI-issuers to be in line with that for the US Real GDP growth (%, yoy) E 2015E EMBI-weighted US Source: Bloomberg, JP Morgan, UBS, as of 25 June 2014 NB: EMBI-weighted GDP growthestimated using current weights, for 9 largest constituents UBS CIO WM July

5 kind toggle bonds remains very low, with less than 2% of the last three months of HY issuance sporting such a structure. We expect default rates to bump along below 2% annualized over the next six months. > > We recommend reducing emerging market hard-currency government bond holdings to underweight. We also recommend reducing emerging market hard-currency government bond (EMBI) holdings to underweight. So far this year, EMBI has delivered performance of more than 8%, partially due to the strong performance of US Treasuries, and partially due to spreads contracting to 280bps. But economic fundamentals in major EM borrowers Brazil, Russia, and Venezuela are deteriorating, and we project GDP growth for EMBI-issuers to be in line with that for the US (see Figure 3). We expect spreads to widen to 330bps over the coming six months. Thank you for reading this CIO Monthly Letter. All feedback is welcome. While there is a different manager signature below, our seasoned professionals remain the same. UBS fields a world-class team that will continue practicing the fundamentals every day in our quest to keep putting the ball in the net. Mark Haefele Global Chief Investment Officer Wealth Management UBS CIO WM July

6 UBS Chief Investment Office WM s investment views are prepared and published by Wealth Management and Retail & Corporate and Wealth Management Americas, Business Divisions of UBS AG (UBS, regulated by FINMA in Switzerland) or an affiliate thereof. In certain countries UBS AG is referred to as UBS SA. This material is for your information only and is not intended as an offer, or a solicitation of an offer, to buy or sell any investment or other specific product. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. Certain services and products are subject to legal restrictions and cannot be offered worldwide on an unrestricted basis and/or may not be eligible for sale to all investors. All information and opinions expressed in this material were obtained from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to its accuracy or completeness (other than disclosures relating to UBS and its affiliates). All information and opinions as well as any prices indicated are current as of the date of this report, and are subject to change without notice. Opinions expressed herein may differ or be contrary to those expressed by other business areas or divisions of UBS as a result of using different assumptions and/or criteria. At any time UBS and other companies in the UBS group (or employees thereof) may have a long or short position, or deal as principal or agent, in relevant securities or provide advisory or other services to the issuer of relevant securities or to a company connected with an issuer. Some investments may not be readily realizable since the market in the securities is illiquid and therefore valuing the investment and identifying the risk to which you are exposed may be difficult to quantify. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS, into other areas, units, divisions or affiliates of UBS. Futures and options trading is considered risky. Past performance of an investment is no guarantee for its future performance. Some investments may be subject to sudden and large falls in value and on realization you may receive back less than you invested or may be required to pay more. Changes in FX rates may have an adverse effect on the price, value or income of an investment. We are of necessity unable to take into account the particular investment objectives, financial situation and needs of our individual clients and we would recommend that you take financial and/or tax advice as to the implications (including tax) of investing in any of the products mentioned herein. This material may not be reproduced or copies circulated without prior authority of UBS or a subsidiary of UBS. UBS expressly prohibits the distribution and transfer of this material to third parties for any reason. UBS will not be liable for any claims or lawsuits from any third parties arising from the use or distribution of this material. This report is for distribution only under such circumstances as may be permitted by applicable law. In developing the Chief Investment Office (CIO) economic forecasts, CIO economists worked in collaboration with economists employed by UBS Investment Research. Forecasts and estimates are current only as of the date of this publication and may change without notice. External Asset Managers / External Financial Consultants: In case this research or publication is provided to an External Asset Manager or an External Financial Consultant, UBS expressly prohibits that it is redistributed by the External Asset Manager or the External Financial Consultant and is made available to their clients and/or third parties. Australia: 1) Clients of UBS Wealth Management Australia Ltd: This notice is distributed to clients of UBS Wealth Management Australia Ltd ABN (Holder of Australian Financial Services Licence No ), Chifley Tower, 2 Chifley Square, Sydney, New South Wales, NSW 2000, by UBS Wealth Management Australia Ltd.: This Document contains general information and/or general advice only and does not constitute personal financial product advice. As such the content of the Document was prepared without taking into account the objectives, financial situation or needs of any specific recipient. Prior to making any investment decision, a recipient should obtain personal financial product advice from an independent adviser and consider any relevant offer documents (including any product disclosure statement) where the acquisition of financial products is being considered. 2) Clients of UBS AG: This notice is issued by UBS AG ABN (Holder of Australian Financial Services Licence No ): This Document is issued and distributed by UBS AG. This is the case despite anything to the contrary in the Document. The Document is intended for use only by Wholesale Clients as defined in section 761G ( Wholesale Clients ) of the Corporations Act 2001 (Cth) ( Corporations Act ). In no circumstances may the Document be made available by UBS AG to a Retail Client as defined in section 761G of the Corporations Act. UBS AG s research services are only available to Wholesale Clients. The Document is general information only and does not take into account any person s investment objectives, financial and taxation situation or particular needs. Austria: This publication is not intended to constitute a public offer or a comparable solicitation under Austrian law and will only be used under circumstances which will not be equivalent to a public offering of securities in Austria. The document may only be used by the direct recipient of this information and may under no circumstances be passed on to any other investor. Bahamas: This publication is distributed to private clients of UBS (Bahamas) Ltd and is not intended for distribution to persons designated as a Bahamian citizen or resident under the Bahamas Exchange Control Regulations. Bahrain: UBS AG is a Swiss bank not licensed, supervised or regulated in Bahrain by the Central Bank of Bahrain and does not undertake banking or investment business activities in Bahrain. Therefore, Clients have no protection under local banking and investment services laws and regulations. Belgium: This publication is not intended to constitute a public offering or a comparable solicitation under Belgian law, but might be made available for information purposes to clients of UBS Belgium, branch of UBS (Luxembourg) SA, registered with the National Bank of Belgian and authorized by the Financial Services and Markets Authority, to which this publication has not been submitted for approval. Brazil: Prepared by UBS Brasil Administradora de Valores Mobiliários Ltda, entity regulated by Comissão de Valores Mobiliários ( CVM ) Canada: In Canada, this publication is distributed to clients of UBS Wealth Management Canada by UBS Investment Management Canada Inc.. Dubai: Research is issued by UBS AG Dubai Branch within the DIFC, is intended for professional clients only and is not for onward distribution within the United Arab Emirates. France: This publication is distributed by UBS (France) S.A., French société anonyme with share capital of , 69, boulevard Haussmann F Paris, R.C.S. Paris B , to its clients and prospects. UBS (France) S.A. is a provider of investment services duly authorized according to the terms of the Code Monétaire et Financier, regulated by French banking and financial authorities as the Autorité de Contrôle Prudentiel et de Résolution. Germany: The issuer under German Law is UBS Deutschland AG, Bockenheimer Landstrasse 2-4, Frankfurt am Main. UBS Deutschland AG is authorized and regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht. Hong Kong: This publication is distributed to clients of UBS AG Hong Kong Branch by UBS AG Hong Kong Branch, a licensed bank under the Hong Kong Banking Ordinance and a registered institution under the Securities and Futures Ordinance. India: Distributed by UBS Securities India Private Ltd. 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) Phone: SEBI Registration Numbers: NSE (Capital Market Segment): INB , NSE (F&O Segment) INF , BSE (Capital Market Segment) INB Indonesia: This research or publication is not intended and not prepared for purposes of public offering of securities under the Indonesian Capital Market Law and its implementing regulations. Securities mentioned in this material have not been, and will not be, registered under the Indonesian Capital Market Law and Regulations. Israel: UBS AG is registered as a Foreign Dealer in cooperation with UBS Wealth Management Israel Ltd, a wholly owned UBS subsidiary. UBS Wealth Management Israel Ltd is a licensed Portfolio Manager which engages also in Investment Marketing and is regulated by the Israel Securities Authority. This publication shall not replace any investment advice and/or investment marketing provided by a relevant licensee which is adjusted to your personal needs. Italy: This publication is distributed to the clients of UBS (Italia) S.p.A., via del vecchio politecnico 3, Milano, an Italian bank duly authorized by Bank of Italy to the provision of financial services and supervised by Consob and Bank of Italy. UBS Italia has not participated in the production of the publication and of the research on investments and financial analysis herein contained. Jersey: UBS AG, Jersey Branch, is regulated and authorized by the Jersey Financial Services Commission for the conduct of banking, funds and investment business. Luxembourg: This publication is not intended to constitute a public offer under Luxembourg law, but might be made available for information purposes to clients of UBS (Luxembourg) S.A., a regulated bank under the supervision of the Commission de Surveillance du Secteur Financier (CSSF), to which this publication has not been submitted for approval. Mexico: This document has been distributed by UBS Asesores México, S.A. de C.V., a company which is not subject to supervision by the National Banking and Securities Commission of Mexico and is not part of UBS Grupo Financiero, S.A. de C.V. or of any other Mexican financial group and whose obligations are not guaranteed by any third party. UBS Asesores México, S.A. de C.V. does not guarantee any yield whatsoever. Netherlands: This publication is not intended to constitute a public offering or a comparable solicitation under Dutch law, but might be made available for information purposes to clients of UBS Bank (Netherlands) B.V., a regulated bank under the supervision of De Nederlansche Bank (DNB) and Autoriteit Financiële Markten (AFM), to which this publication has not been submitted for approval. Singapore: Please contact UBS AG Singapore branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or report. Spain: This publication is distributed to clients of UBS Bank, S.A. by UBS Bank, S.A., a bank registered with the Bank of Spain. Taiwan: This document is distributed to qualified clients of UBS Securities Pte. Ltd., Taipei Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Taipei Branch. UAE: This research report is not intended to constitute an offer, sale or delivery of shares or other securities under the laws of the United Arab Emirates (UAE). The contents of this report have not been and will not be approved by any authority in the United Arab Emirates including the UAE Central Bank or Dubai Financial Authorities, the Emirates Securities and Commodities Authority, the Dubai Financial Market, the Abu Dhabi Securities market or any other UAE exchange. UK: Approved by UBS AG, authorised and regulated by the Financial Market Supervisory Authority in Switzerland. In the United Kingdom, UBS AG is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. A member of the London Stock Exchange. This publication is distributed to private clients of UBS London in the UK. Where products or services are provided from outside the UK, they will not be covered by the UK regulatory regime or the Financial Services Compensation Scheme. USA: This document is not intended for distribution into the US and / or to US persons. UBS Securities LLC is a subsidiary of UBS AG and an affiliate of UBS Financial Services Inc., UBS Financial Services Inc. is a subsidiary of UBS AG. Version 03/2014. UBS The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved. UBS CIO WM July

UBS Compensation Survey 2017

UBS Compensation Survey 2017 Public UBS Compensation Survey 2017 Outlook Dr. Daniel Kalt UBS Chief Economist & Chief Investment Officer Switzerland October 26, 2016 Economic environment Real Gross Domestic Product (Index Q1 2005 =

More information

UK economy. BREXIT: into the final furlong. Dean Turner, CFA Economist CIO WM UK UBS Wealth Management. Source: istock

UK economy. BREXIT: into the final furlong. Dean Turner, CFA Economist CIO WM UK UBS Wealth Management. Source: istock UK economy BREXIT: into the final furlong Dean Turner, CFA Economist CIO WM UK UBS Wealth Management Source: istock March 2016 The polls have narrowed, but "remain" still in the lead. Our BREXIT probability

More information

Annual UBS investment Lecture. Welcome

Annual UBS investment Lecture. Welcome City Guest Wifi password: tglhkjni Annual UBS investment Lecture Thursday 17 November 2016 Welcome Public Economic and Investment Outlook Dean Turner, CFA Economist Chief Investment Office, WM November

More information

UBS House View. Treasurers Forum the year ahead. November Chief Investment Office WM. Published 3 November 2015

UBS House View. Treasurers Forum the year ahead. November Chief Investment Office WM. Published 3 November 2015 UBS House View Chief Investment Office WM Treasurers Forum the year ahead November 2015 Published 3 November 2015 This report has been prepared by UBS AG. Please see the important disclaimer at the end

More information

Dr. Andreas Höfert, UBS Chief Economist. Swiss American Chamber of Commerce Zurich, October 30, 2009

Dr. Andreas Höfert, UBS Chief Economist. Swiss American Chamber of Commerce Zurich, October 30, 2009 UBS compensation survey Outlook 2010 Dr. Andreas Höfert, UBS Chief Economist Swiss American Chamber of Commerce Zurich, October 30, 2009 US equity markets: Havoc after Lehman Brothers collapse Index Percent

More information

UBS CIO Houseview and Year ahead

UBS CIO Houseview and Year ahead UBS CIO Houseview and Year ahead November 2017 Themis Themistocleous Head, European CIO November 2017 Section 1: Global outlook and positioning CIO key view Global growth is accelerating Real GDP growth

More information

CIO WM Research. Swiss Chartset Last update: 8 January 2014

CIO WM Research. Swiss Chartset Last update: 8 January 2014 CIO WM Research Swiss Chartset Last update: 8 January 2014 Contents Section 1 Economy 2 Section 2 Prices, Interest Rates, Exchange Rates, Monetary Indicators 27 Section 3 Switzerland in international comparison

More information

Chief economist's comment

Chief economist's comment Chief economist's comment No confidence in confidence data? Chief Investment Office WM 20 April 2017 Paul Donovan, Global Chief Economist WM, paul.donovan@ubs.com Financial markets love confidence numbers.

More information

Swiss Chartset. Last update: 07 September 2018

Swiss Chartset. Last update: 07 September 2018 Swiss Chartset Last update: 07 September 2018 This report has been prepared by UBS Switzerland AG. Please see the important disclaimer at the end of the document. This chartset should be read in conjunction

More information

Chief economist's comment

Chief economist's comment Chief economist's comment What can we forecast about next year? Chief Investment Office WM 11 December 2017 2:01 pm GMT Paul Donovan, Global Chief Economist WM, paul.donovan@ubs.com Economic forecasts

More information

Chief economist's comment

Chief economist's comment Chief economist's comment Are bond traders better than economists? Chief Investment Office WM 01 August 2018 3:49 pm BST Paul Donovan, Global Chief Economist GWM, paul.donovan@ubs.com No, bond traders

More information

Sustainable investing

Sustainable investing Sustainable investing Investing for Good Michaela Seimen Howat, CIO Sustainable Investing, UBS Wealth Management September 2018 Sustainable & Impact investments are investments made with the intention

More information

Swiss real estate market

Swiss real estate market UBS Swiss Real Estate Index 4Q- Chief Investment Office WM 7 February 2018 Translation: Matthias Holzhey, Economist, matthias.holzhey@ubs.com; Claudio Saputelli, Economist, claudio.saputelli@ubs.com; Maciej

More information

Chief economist's comment

Chief economist's comment Chief economist's comment What's happening everywhere else? Chief Investment Office WM 28 January 2019 7:47 pm GMT Paul Donovan, Global Chief Economist GWM, paul.donovan@ubs.com The growth in demand in

More information

UBS CIO Monthly Letter

UBS CIO Monthly Letter ab Chief Investment Officer Wealth Management August 213 UBS CIO Monthly Letter The changing winds Alexander S. Friedman Global CIO UBS WM Summer has finally arrived in Europe, and many of us are heading

More information

Chinese equities. A-shares join MSCI's index universe

Chinese equities. A-shares join MSCI's index universe A-shares join MSCI's index universe Chief Investment Office WM 21 June 2017 Hyde Chen, CFA, analyst, hyde.chen@ubs.com; Louisa Fok, CFA, analyst, louisa.fok@ubs.com MSCI has decided to include Chinese

More information

Chief economist's comment

Chief economist's comment Chief economist's comment Pride and Prejudice, and Economists Chief Investment Office WM 27 June 2018 10:54 pm BST Paul Donovan, Global Chief Economist GWM, paul.donovan@ubs.com Pride month is a series

More information

US equities. Will the Amazon, JP Morgan and Berkshire venture change healthcare?

US equities. Will the Amazon, JP Morgan and Berkshire venture change healthcare? Will the Amazon, JP Morgan and Berkshire venture change healthcare? Chief Investment Office WM 30 January 2018 6:17 pm GMT Jerome Brimeyer, Healthcare Equity Sector Strategist Americas; Bradley Ball, Financials

More information

UBS HouseView. Bubble thoughts. Digest. US Edition CIO Wealth Management Research. December 2013

UBS HouseView. Bubble thoughts. Digest. US Edition CIO Wealth Management Research. December 2013 UBS HouseView Digest Edition CIO Wealth Management Research December 2013 Bubble thoughts Bubble thoughts Five years ago the Federal Reserve announced its first round of quantitative easing (QE). QE has

More information

Becton Dickinson & Co

Becton Dickinson & Co 09/17E UBS 214 224 255 257 950 1042 1110 Becton Dickinson & Co UnitedStatesofAmerica/HealthcareEquipment &Supplies 2February2017 UBS Research Jonathan Groberg, IB Analyst Harris Iqbal Solidquarter,despiteFX

More information

Future of food demand

Future of food demand Public Future of food demand Southeast Asia and Africa grain growers' brightest hope Mr. Wayne Gordon Executive Director April 2017 Agriculture's greatest challenge: Lower real returns Short term, agriculture

More information

Global economy. Italy and the euro are investors lost in translation?

Global economy. Italy and the euro are investors lost in translation? Italy and the euro are investors lost in translation? Chief Investment Office WM 04 June 2018 10:51 pm BST Matteo Ramenghi, Chief Investment Officer UBS WM Italy, matteo.ramenghi@ubs.com; Ricardo Garcia,

More information

Closed-end fund update

Closed-end fund update ab Closed-end fund update Update on Convertible Funds: Asset Composition UBS Wealth Management Research / 29 July 2008 Lead Analyst Sangeeta Marfatia Highlights In recent weeks we have seen pressure from

More information

Pricing Guidelines for Listed Products and OTC Derivatives Clearing Services offered by UBS EMIR Articles 38(1) and 39(7)

Pricing Guidelines for Listed Products and OTC Derivatives Clearing Services offered by UBS EMIR Articles 38(1) and 39(7) For Professional Clients/Institutional Investors Only Pricing Guidelines for Listed Products and OTC Derivatives Clearing Services offered by UBS EMIR Articles 38(1) and 39(7) 1. Introduction The European

More information

Chief economist's comment

Chief economist's comment Chief economist's comment Are trade taxes changing trade? Chief Investment Office WM 21 November 2018 7:16 pm GMT Paul Donovan, Global Chief Economist GWM, paul.donovan@ubs.com Globalization had peaked

More information

Teva Pharmaceuticals

Teva Pharmaceuticals UBS 520 590 560 Israel/Pharmaceuticals 6January2017 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst 2017GuidanceWorseThanExpected Our takeaway: Still so many questions Additional takeaway Thoughts

More information

Johnson & Johnson. UnitedStatesofAmerica/Pharmaceuticals 10February2017. PositiveXareltoStudyAddsTailwindtoPharma Estimates

Johnson & Johnson. UnitedStatesofAmerica/Pharmaceuticals 10February2017. PositiveXareltoStudyAddsTailwindtoPharma Estimates 12/17E UBS 180 188 178 153 700 749 792 Johnson & Johnson UnitedStatesofAmerica/Pharmaceuticals 10February2017 UBS Research Matt Miksic, IB Analyst Vik Chopra, IB Analyst PositiveXareltoStudyAddsTailwindtoPharma

More information

UBS CIO Monthly Letter

UBS CIO Monthly Letter ab Chief Investment Officer Wealth Management June 13 Ice-skating through the markets Alexander S. Friedman Global CIO UBS WM When I was young, I liked to ice skate on a pond near our house. I learned

More information

Chief economist's comment

Chief economist's comment Chief economist's comment Will recessions be less recessionary in the future? Chief Investment Office WM 25 July 2017 Paul Donovan, Global Chief Economist WM, paul.donovan@ubs.com Recessions tend to be

More information

French Election Watch

French Election Watch En Marche! CIO WM Research 7 May 2017 Dean Turner, CFA, economist; Ricardo Garcia, economist; Themis Themistocleous, Regional CIO Europe; Thomas Wacker, CFA, analyst; Bert Jansen, strategist; Thomas Flury,

More information

Bristol-Myers Squibb

Bristol-Myers Squibb 12/16E UBS 074 069 077 068 288 300 310 Bristol-Myers Squibb UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 26January2017 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst 4QMiss;NumbersComingDownSome

More information

Baxter International Inc.

Baxter International Inc. ...12/17E..From. Baxter International Inc. UnitedStatesofAmerica/Equipment&Services 1February2017 UBS Research Matt Miksic, IB Analyst Vik Chopra, IB Analyst PostQ3CallTakeaways Solid beat, outlook calls

More information

Global economy. Is a trade war likely? The trade debate in May

Global economy. Is a trade war likely? The trade debate in May Is a trade war likely? The trade debate in May Chief Investment Office WM 08 May 2018 8:17 pm BST Paul Donovan, Global Chief Economist WM, paul.donovan@ubs.com; Yifan Hu, Regional CIO and Chief China Economist,

More information

Direct Execution UBS ATS. Rules of Engagement Addendum for Conditional Indications

Direct Execution UBS ATS. Rules of Engagement Addendum for Conditional Indications Direct Execution UBS ATS Rules of Engagement Addendum for Conditional Indications March 14, 2017 UBS RoE Addendum 03142017.docx Table of Contents 1 Introduction 1 2 Overview 1 2.1 Initial Transmission

More information

Energy. North American energy independence: reenergized 22 March disclosures that begin on page 5.

Energy. North American energy independence: reenergized 22 March disclosures that begin on page 5. North American energy independence: reenergized 22 March 2016 CIO WM Research Nicole Decker, Equity Sector Strategist, nicole.decker@ubs.com; David Lefkowitz, CFA, Senior Equity Strategist, david.lefkowitz@ubs.com

More information

UBS House View. Preparing for the second half. Monthly Letter. Risks ahead. First half scorecard. Shifting growth.

UBS House View. Preparing for the second half. Monthly Letter. Risks ahead. First half scorecard. Shifting growth. UBS House View Monthly Letter 21 June 218 Chief Investment Office GWM Investment Research First half scorecard Risks ahead Shifting growth Asset allocation Global stocks managed to grind higher in the

More information

Long-duration: Volatility in isolation, safety in context Blog

Long-duration: Volatility in isolation, safety in context Blog 17 December 2018, 10:06PM UTC Chief Investment Office GWM Investment Research Long-duration: Volatility in isolation, safety in context Blog In this month's House View letter, we closed our overweight

More information

Johnson & Johnson. UnitedStatesofAmerica/Pharmaceuticals 15February2017. Q1U.S.PharmaTrendsOfftoaStrongStart

Johnson & Johnson. UnitedStatesofAmerica/Pharmaceuticals 15February2017. Q1U.S.PharmaTrendsOfftoaStrongStart 12/17E UBS 180 188 178 153 700 749 792 Johnson & Johnson UnitedStatesofAmerica/Pharmaceuticals 15February2017 UBS Research Matt Miksic, IB Analyst Vik Chopra, IB Analyst Q1USPharmaTrendsOfftoaStrongStart

More information

1. Introduction. 2. Client Profitability

1. Introduction. 2. Client Profitability For Professional Clients/Institutional Investors Only Pricing Guidelines for Listed Products and OTC Derivatives Clearing Services offered by UBS EMIR Articles 38(1) and 39(7) and Markets in Financial

More information

UBS House View. Teaming up to perform. Switzerland faces challenges. Investor s Guide with recommended solutions. Switzerland CIO Wealth management

UBS House View. Teaming up to perform. Switzerland faces challenges. Investor s Guide with recommended solutions. Switzerland CIO Wealth management UBS House View Investor s Guide with recommended solutions For investors domiciled in Switzerland Switzerland CIO Wealth management July 2014 Teaming up to perform SPOTLIGHT Switzerland faces challenges

More information

Lilly (Eli) & Co. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 15December2016. SlightlyBetterThanExpected2017Guidance

Lilly (Eli) & Co. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 15December2016. SlightlyBetterThanExpected2017Guidance 12/16E UBS 083 086 088 097 354 400 440 Lilly (Eli) & Co UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 15December2016 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst SlightlyBetterThanExpected2017Guidance

More information

Pfizer Inc. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 31January2017. In-Line4Q;GuidanceWeakerduetoFX

Pfizer Inc. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 31January2017. In-Line4Q;GuidanceWeakerduetoFX 12/16E UBS 067 064 061 048 240 265 285 Pfizer Inc UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 31January2017 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst In-Line4Q;GuidanceWeakerduetoFX

More information

UBS Forum. Sharper opinions, smarter decisions

UBS Forum. Sharper opinions, smarter decisions Thursday, February 5 2015 UBS Forum. Sharper opinions, smarter decisions Madrid Milan London Frankfurt Zurich Chief Investment Office WM The Diverging World CIO Year Ahead 2015 Bill O'Neill Head of Investment

More information

Smith & Nephew. UnitedKingdom/HealthcareEquipment& Supplies 9February2017. Q4&H2largelyinline.GuidanceOK.

Smith & Nephew. UnitedKingdom/HealthcareEquipment& Supplies 9February2017. Q4&H2largelyinline.GuidanceOK. UBS 7964 8670 9366 Smith & Nephew UnitedKingdom/HealthcareEquipment& Supplies 9February2017 UBS Research Ian Douglas-Pennant, IB Analyst Sebastian Walker, IB Analyst Q4&H2largelyinlineGuidanceOK Q: How

More information

Bristol-Myers Squibb

Bristol-Myers Squibb ...12/17E..From. Bristol-Myers Squibb UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 1February2017 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst EUGenericSprycelImpactShouldBeModest

More information

Stryker Corporation. UnitedStatesofAmerica/Equipment&Services 26February2016. AddingScaletoMedical,EnhancingGrowth

Stryker Corporation. UnitedStatesofAmerica/Equipment&Services 26February2016. AddingScaletoMedical,EnhancingGrowth UnitedStatesofAmerica/Equipment&Services 26February2016 UBS Research Matt Miksic, IB Analyst Vik Chopra, IB Analyst AddingScaletoMedical,EnhancingGrowth Physio-Contol deal expands EMS portfolio Street

More information

Sanofi. France/Pharmaceuticals 16February2017. ModelupdatepostFY2016results(PriceTargetto 82from 78,Neutralratingretained)

Sanofi. France/Pharmaceuticals 16February2017. ModelupdatepostFY2016results(PriceTargetto 82from 78,Neutralratingretained) ..From Sanofi France/Pharmaceuticals 16February2017 UBS Research Jack Scannell, IB Analyst Michael Leuchten, IB Analyst ModelupdatepostFY2016results(PriceTargetto 82from 78,Neutralratingretained) We are

More information

Fresenius SE & Co KGaA

Fresenius SE & Co KGaA UBS 302 329 369 Fresenius SE & Co KGaA Germany/HealthcareProviders&Services 2August2016 UBS Research Ian Douglas-Pennant, IB Analyst Sebastian Walker, IB Analyst Guidanceraiseasexpected Q: How did the

More information

European economy. Spain: A fading tourism boom

European economy. Spain: A fading tourism boom Spain: A fading tourism boom Chief Investment Office WM 07 May 2018 4:29 pm BST Roberto Scholtes Ruiz, Chief Investment Officer Spain, roberto.ruiz-scholtes@ubs.com Tourist arrivals to Spain rose notably

More information

Longer Term Investments

Longer Term Investments Automation and robotics - Spotlight on artificial intelligence Chief Investment Office WM 22 August 2016 Sundeep Gantori, CFA, CAIA, analyst, sundeep.gantori@ubs.com; Alexander Stiehler, CFA, analyst,

More information

Fresenius Medical Care

Fresenius Medical Care UBS 34 41 47 Germany/HealthcareProviders&Services 19July2016 UBS Research Ian Douglas-Pennant, IB Analyst Sebastian Walker, IB Analyst Someinsightintobundlinglobbyingefforts? DaVita supports new PATIENT

More information

Charting the Course. Can MXAPJ Sustain Jan Rally? Rotational Opportunities Best; Asia Technicals Strategy

Charting the Course. Can MXAPJ Sustain Jan Rally? Rotational Opportunities Best; Asia Technicals Strategy Charting the Course Can MXAPJ Sustain Jan Rally? Rotational Opportunities Best; Asia Technicals Strategy Priced on 01 Feb 2012 Asia Technical Analysis Research AC J.P. Morgan Securities (Asia Pacific)

More information

Global Fixed Income Weekly

Global Fixed Income Weekly Global Fixed Income Weekly Executive Summary US nonfarm payroll employment rose by 103,000 in March, falling short of consensus expectations by 82,000; the undershoot is likely due to weather effects and

More information

FLASH NOTE EURO AREA: ECONOMIC ACTIVITY WHAT IF CAR TARIFFS LIE AHEAD? SUMMARY

FLASH NOTE EURO AREA: ECONOMIC ACTIVITY WHAT IF CAR TARIFFS LIE AHEAD? SUMMARY Author NADIA GHARBI, CFA ngharbi@pictet.com SUMMARY Among the key risks for our euro area outlook, the threat of US auto tariffs is of major importance. The US Commerce Department s investigation on national

More information

Investing in Mexico. Monthly strategy update

Investing in Mexico. Monthly strategy update CIO WM Research 9 September 2013 Investing in Mexico Monthly strategy update The uncertainty in the timing of the US Federal Reserve's decision to reduce its asset purchases are still weighing on EM assets.

More information

Flash Note Currencies: EUR/USD

Flash Note Currencies: EUR/USD FLASH NOTE Flash Note Currencies: EUR/USD Short-term hurdles to euro strength Pictet Wealth Management - Asset Allocation & Macro Research 18 June 2018 The ECB s commitment on rates announced at its June

More information

Portfolio principles. Loss-harvesting to save taxes 4 October begin on page 4.

Portfolio principles. Loss-harvesting to save taxes 4 October begin on page 4. Loss-harvesting to save taxes 4 October 2018 Chief Investment Office Americas, Wealth Management Kathleen McNamara, CFA, CFP, Senior Municipal Strategist Americas, kathleen.mcnamara@ubs.com We provide

More information

Teva Pharmaceuticals

Teva Pharmaceuticals UBS 585 620 603 Israel/Pharmaceuticals 12April2016 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst EMAApprovesGenericCopaxone20mg What s new? Synthon obtains EU approval for generic Copaxone

More information

All-Country Equity Allocator February 2018

All-Country Equity Allocator February 2018 Leila Heckman, Ph.D. lheckman@dcmadvisors.com 917-386-6261 John Mullin, Ph.D. jmullin@dcmadvisors.com 917-386-6262 Charles Waters cwaters@dcmadvisors.com 917-386-6264 All-Country Equity Allocator February

More information

Flash Note Euro area: Q2 GDP growth

Flash Note Euro area: Q2 GDP growth FLASH NOTE Flash Note Euro area: Q2 GDP growth Revising our 2018 GDP growth forecast down to 2.0% Pictet Wealth Management - Asset Allocation & Macro Research 31 July 2018 Euro area GDP growth unexpectedly

More information

Swiss economy. Global risks to weigh on Swiss growth

Swiss economy. Global risks to weigh on Swiss growth Global risks to weigh on Swiss growth Chief Investment Office WM 8 November 8 7: am GMT+: Translation: November 8 Alessandro Bee, Economist, alessandro.bee@ubs.com The Swiss economy is likely to grow by.6%

More information

All-Country Equity Allocator July 2018

All-Country Equity Allocator July 2018 Leila Heckman, Ph.D. lheckman@dcmadvisors.com 917-386-6261 John Mullin, Ph.D. jmullin@dcmadvisors.com 917-386-6262 Allison Hay ahay@dcmadvisors.com 917-386-6264 All-Country Equity Allocator July 2018 A

More information

Cash Alternatives. Liquidity Solutions. 1. Introduction

Cash Alternatives. Liquidity Solutions. 1. Introduction Liquidity Solutions Chief Investment Office Americas, Wealth Management 07 September 2018 6:59 pm BST Leslie Falconio, Senior Fixed Income Strategist Americas, leslie.falconio@ubs.com; Ronald Sutedja,

More information

Chief Investment Office WM 19 September 2014

Chief Investment Office WM 19 September 2014 Chief Investment Office WM 19 September 2014 Subordinated bonds Volatility to persist Corporate hybrids have recouped their losses since the summer sell-off. Investment grade rated instruments returned

More information

FLASH NOTE EUROPE CHART OF THE WEEK: GERMAN GROWTH A BLIP OR SOMETHING MORE? SUMMARY

FLASH NOTE EUROPE CHART OF THE WEEK: GERMAN GROWTH A BLIP OR SOMETHING MORE? SUMMARY Author NADIA GHARBI, CFA ngharbi@pictet.com SUMMARY German GDP figures showed that the German economy contracted in Q3 for the first time since Q1 2015 but markets were prepared. Economic activity was

More information

Johnson & Johnson. UnitedStatesofAmerica/Pharmaceuticals 23November2015. UpdatingEstimatesforDaraandPharmaTrends

Johnson & Johnson. UnitedStatesofAmerica/Pharmaceuticals 23November2015. UpdatingEstimatesforDaraandPharmaTrends ...12/15E..From. Johnson & Johnson UnitedStatesofAmerica/Pharmaceuticals 23November2015 UBS Research Matt Miksic, IB Analyst Vik Chopra, IB Analyst UpdatingEstimatesforDaraandPharmaTrends Upping estimates

More information

UBS Economics Day The Australian Budget

UBS Economics Day The Australian Budget UBS Economics Day The Australian 2015-16 Budget Andrew Lilley Interest Rate Strategist andrew.lilley@ubs.com This document has been prepared by UBS Securities Australia Ltd. ANALYST CERTIFICATION AND REQUIRED

More information

Bristol-Myers Squibb

Bristol-Myers Squibb 12/16E UBS 063 062 059 051 235 310 400 UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 28April2016 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst OpdivoDrivesaNiceBeatandRaise

More information

UBS Outlook Switzerland

UBS Outlook Switzerland UBS Outlook Switzerland Outlook 2019 November 2018 Chief Investment Office GWM Financial analysis Short version For investors domiciled in Switzerland UBS Outlook Switzerland 4Q 2018 Please see the important

More information

URBANISATION AND RESOURCE INTENSITY

URBANISATION AND RESOURCE INTENSITY URBANISATION AND RESOURCE INTENSITY Carsten Menke, CFA UZH Sustainable Urban Growth Conference, Zurich, 8 September 2015 Please find important legal information at the end of this document URBANISATION

More information

Allergan Plc. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 26April2016. AllerganShouldBeaCoreHoldingAgain

Allergan Plc. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 26April2016. AllerganShouldBeaCoreHoldingAgain 12/16E UBS 298 337 376 424 1435 1900 2300 UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 26April2016 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst AllerganShouldBeaCoreHoldingAgain

More information

Australian & Global Equity Market Outlook

Australian & Global Equity Market Outlook UBS Investment Research Australian & Global Equity Market Outlook David Cassidy 9324 3721 UBS Australian Equity Strategy April 2011 This material has been prepared by UBS Securities Australia Ltd ANALYST

More information

S&P Dow Jones Disclaimer

S&P Dow Jones Disclaimer S&P Dow Jones Disclaimer S&P Dow Jones Disclaimer: The State Street Liquid Private Equity Sector Select Investable Indices (the Index ) is the property of State Street Bank and Trust which has contracted

More information

Modern retirement monthly

Modern retirement monthly Healthcare in retirement 7 August 2017 Chief Investment Office Americas, Wealth Management Michael Crook, Head Americas UHNW and Institutional Strategy, michael.crook@ubs.com Most Americans have not accounted

More information

Flash Note Switzerland: Q2 GDP growth

Flash Note Switzerland: Q2 GDP growth FLASH NOTE Flash Note Switzerland: Q2 GDP growth The devil is in the details Pictet Wealth Management - Asset Allocation & Macro Research 7 September 2018 Yes, the Swiss economy is booming. GDP grew by

More information

Brazil Economic Outlook for 2013

Brazil Economic Outlook for 2013 Emerging Markets Research January 13 Brazil Economic Outlook for 13 Luis Oganes Head of Latin America Research Growth-inflation dilemma: Brazil s growth expected to remain below potential through 1Q13

More information

Video March 1, StratTV at the TMT Conference. Watch the video: Related Research

Video March 1, StratTV at the TMT Conference. Watch the video: Related Research March 1, 2016 Video StratTV at the TMT Conference MORGAN STANLEY & CO. LLC Adam S. Parker, Ph.D. Adam.Parker@morganstanley.com Video March 1, 2016 +1 212 761-1755 Watch the video: Related Research US Equity

More information

FOR 2018 GLOBAL MARKET OUTLOOK PRESS BRIEFING. PROVIDED TO DESIGNATED MEMBERS OF THE PRESS ONLY, NOT FOR FURTHER DISTRIBUTION.

FOR 2018 GLOBAL MARKET OUTLOOK PRESS BRIEFING. PROVIDED TO DESIGNATED MEMBERS OF THE PRESS ONLY, NOT FOR FURTHER DISTRIBUTION. 2018 Global Market Outlook Press Briefing GLOBAL FIXED INCOME Mark Vaselkiv Portfolio Manager, CIO, Fixed Income November 14, 2017 FOR 2018 GLOBAL MARKET OUTLOOK PRESS BRIEFING. PROVIDED TO DESIGNATED

More information

Investment Product Guide- Interest Rate Swap (IRS)

Investment Product Guide- Interest Rate Swap (IRS) Investment Product Guide- Interest Rate Swap (IRS) I have read the Investment Product Guide of the above product, and I acknowledge that I understand its features and risks. Signature: Print Name: Date:

More information

Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings, Inc. 12/16E UBS 200 195 180 218 793 884 979 Zimmer Biomet Holdings, Inc UnitedStatesofAmerica/Equipment&Services 7June2016 UBS Research Matt Miksic, IB Analyst Vik Chopra, IB Analyst ZBHWranglesinLDRH;EnhancingSpine

More information

Seventh City of London Biennial Meeting 2013

Seventh City of London Biennial Meeting 2013 Seventh City of London Biennial Meeting 2013 Looking Ahead with Optimism and Realism The World in Recovery: Global Currency Trends George Athanasopoulos Group Managing Director Co-Head of Global Foreign

More information

Flash Economics. The end of quantitative easing in the euro zone: Will banks step in for the ECB to buy government bonds?

Flash Economics. The end of quantitative easing in the euro zone: Will banks step in for the ECB to buy government bonds? 8 November 7-7 The end of quantitative easing in the euro zone: Will banks step in for the ECB to buy government bonds? As the ECB probably will stop quantitative easing in the euro zone in 8, it will

More information

Global Select International Select International Select Hedged Emerging Market Select

Global Select International Select International Select Hedged Emerging Market Select International Exchange Traded Fund (ETF) Managed Strategies ETFs provide investors a liquid, transparent, and low-cost avenue to equities around the world. Our research has shown that individual country

More information

Lilly (Eli) & Co. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 18January2017. AddingAnotherStrategicAsset

Lilly (Eli) & Co. UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 18January2017. AddingAnotherStrategicAsset 12/16E UBS 083 086 088 100 357 415 440 Lilly (Eli) & Co UnitedStatesofAmerica/Pharmaceuticals, Biotechnology&LifeSciences 18January2017 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst AddingAnotherStrategicAsset

More information

Boston Scientific Corp.

Boston Scientific Corp. 12/16E UBS 024 026 027 028 105 115 124 Boston Scientific Corp UnitedStatesofAmerica/HealthcareEquipment &Supplies 26April2016 UBS Research Matt Miksic, IB Analyst Vik Chopra, IB Analyst MRI-SafeApprovalPositive,PositionsBSXto

More information

Why invest in floating rate bonds?

Why invest in floating rate bonds? For professional clients / qualified investors only Why invest in floating rate bonds? The current economic environment is shifting. In our view, we are moving towards a scenario in which investors should

More information

Table 1: Foreign exchange turnover: Summary of surveys Billions of U.S. dollars. Number of business days

Table 1: Foreign exchange turnover: Summary of surveys Billions of U.S. dollars. Number of business days Table 1: Foreign exchange turnover: Summary of surveys Billions of U.S. dollars Total turnover Number of business days Average daily turnover change 1983 103.2 20 5.2 1986 191.2 20 9.6 84.6 1989 299.9

More information

Flash Note Japan: Second reading of Q2 GDP

Flash Note Japan: Second reading of Q2 GDP FLASH NOTE Flash Note Japan: Second reading of Q2 GDP GDP forecast revised up but external uncertainties persist Pictet Wealth Management - Asset Allocation & Macro Research 11 September 2018 The second

More information

UBS CIO Monthly Letter

UBS CIO Monthly Letter ab Chief Investment Officer Wealth Management April 13 The global tricycle Alexander S. Friedman Global CIO UBS WM As I write this letter, the newspaper headlines are full of alarming stories about Cyprus

More information

Smith & Nephew. UnitedKingdom/HealthcareEquipment& Supplies 5May2016. China&MiddleEastimpactgreaterthan thought

Smith & Nephew. UnitedKingdom/HealthcareEquipment& Supplies 5May2016. China&MiddleEastimpactgreaterthan thought UBS 8361 8678 9450 Smith & Nephew UnitedKingdom/HealthcareEquipment& Supplies 5May2016 UBS Research Ian Douglas-Pennant, IB Analyst Sebastian Walker, IB Analyst China&MiddleEastimpactgreaterthan thought

More information

Teva Pharmaceuticals

Teva Pharmaceuticals ..From Israel/Pharmaceuticals 9May2016 UBS Research Marc Goodman, IB Analyst Ami Fadia, IB Analyst OnTracktoClosetheAllerganDeal Key takeaways from the conference call Additional takeaways Thoughts on

More information

EUROPEAN EQUITIES: gaining traction?

EUROPEAN EQUITIES: gaining traction? Market insight: EUROPEAN EQUITIES: gaining traction? European equities have lagged behind the US market could this change? SEPTEMBER 2015 Please see pages 14-17 for important disclosures and definitions

More information

Flash Economics. The acceleration in global trade is very good for the euro zone; what accounts for it?

Flash Economics. The acceleration in global trade is very good for the euro zone; what accounts for it? 1 July 17 - The acceleration in global trade is very good for the euro zone; what accounts for it? Since the second half of 1, global trade in volume terms has accelerated, lifting euro-zone exports. First,

More information